Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2024

Pharma News, 2024

New report demands greater understanding of the impact of change on academia

New report demands greater understanding of the impact of change on academia

Digital Science, a technology company serving stakeholders across the research ecosystem, is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having ...

Social media engagement boosts rare disease outreach

Social media engagement boosts rare disease outreach

Social media has become an excellent tool for targeting specific patients for clinical trials, says Chris Adams, the CEO at Andarix Pharmaceuticals, a biotech developing targeted oncology therapies.

Pharma companies must adapt to keep pace with AI developments, say experts

Pharma companies must adapt to keep pace with AI developments, say experts

At the Outsourcing in Clinical Trials Conference, key opinion leaders shared predictions for workflow changes due to AI.

This Is Huge News for Novo Nordisk

This Is Huge News for Novo Nordisk

Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus. Rybelsus is an oral glucagon-like peptide-1 (GLP-1) agonist and sibling medication to ...

J&J, Eli Lilly pad immunology profiles with trial readouts in new patient groups

J&J, Eli Lilly pad immunology profiles with trial readouts in new patient groups

With new readouts, Johnson & Johnson's Tremfya and Eli Lilly's Ebglyss are further proving their worth in separate immunology areas. Key drugs from Johnson & Johnson and Eli Lilly stand to...

Taurine reduces atherosclerotic plaque area and stability in mice

Taurine reduces atherosclerotic plaque area and stability in mice

Previous studies suggest that taurine (2-aminoethanesulfonic acid) supplementation may attenuate atherosclerosis by reducing lipid levels. However, energy drinks containing taurine have been s...

After prior rejection, Iterum nabs long-sought FDA nod for oral UTI drug Orlynvah

After prior rejection, Iterum nabs long-sought FDA nod for oral UTI drug Orlynvah

Despite recent concerns from the FDA about potential off-label use and antimicrobial resistance, Dublin-based Iterum Therapeutics has scored a green light for its oral antibiotic sulopenem. Sulopenem,...

Study shows diabetes drug Ozempic also has positive effect in chronic kidney disease

Study shows diabetes drug Ozempic also has positive effect in chronic kidney disease

The diabetes drug semaglutide, also known as Ozempic, has a positive effect on patients with chronic kidney disease and obesity. The amount of protein in their urine decreased, as did the degree of in...

MIRA Pharmaceuticals reports promising preclinical study

MIRA Pharmaceuticals reports promising preclinical study

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) has announced significant findings in a recent preclinical study.

FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years

FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years

Pfizer's Abrysvo is FDA-approved to prevent RSV in adults 18-59 at high risk. Abrysvo remains the only RSV vaccine approved for pregnant individuals to protect infants.

ORIC-114 shows promise in preclinical cancer study

ORIC-114 shows promise in preclinical cancer study

SOUTH SAN FRANCISCO - ORIC Pharmaceuticals, Inc., a clinical-stage company focusing on cancer treatment resistance, has presented preclinical data on its drug candidate ORIC-114 at the EORTC-NCI-AACR ...

First patient to receive breakthrough sickle cell gene therapy leaves hospital

First patient to receive breakthrough sickle cell gene therapy leaves hospital

First patient to receive breakthrough sickle cell gene therapy leaves hospital

1 2 3 456 7 8 9